{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:51:10Z","timestamp":1787237470613,"version":"build-2736575974"},"reference-count":83,"publisher":"Oxford University Press (OUP)","issue":"5","funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Antimicrobial drug resistance is spreading among Enterobacteriaceae, limiting the utility of traditionally used agents. We sought to systematically review the microbiological activity and clinical effectiveness of tigecycline for multidrug-resistant (MDR) Enterobacteriaceae, including those resistant to broad-spectrum \u03b2-lactams due to the expression of extended-spectrum \u03b2-lactamases (ESBLs), AmpC enzymes and carbapenemases (including metallo-\u03b2-lactamases).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed was searched for articles including relevant data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-six microbiological and 10 clinical studies were identified. Tigecycline was active against more than 99% of 1936 Escherichia coli isolates characterized by any of the above resistance patterns (including 1636 ESBL-producing isolates) using the US Food and Drug Administration (FDA) breakpoint of susceptibility (MIC \u2264 2 mg\/L). Findings were not different using the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoint (\u22641 mg\/L). Susceptibility rates for Klebsiella spp. with any of the above resistance patterns were 91.2% for 2627 isolates by the FDA criteria and 72.3% for 1504 isolates by the EUCAST criteria (92.3% for 2030 and 72.3% for 1284 ESBL-producing isolates, by the FDA and EUCAST criteria, respectively). The degree of microbiological activity of tigecycline against 576 MDR Enterobacter spp. isolates was moderate. In clinical studies, 69.7% of the 33 reported patients treated with tigecycline achieved resolution of an infection caused by a carbapenem-resistant or ESBL-producing or MDR Enterobacteriaceae.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tigecycline is microbiologically active against almost all of the ESBL or MDR E. coli isolates and the great majority of ESBL or MDR Klebsiella spp. isolates. Further evaluation of its clinical utility against such resistant Enterobacteriaceae, particularly regarding non-labelled indications, is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkn311","type":"journal-article","created":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T20:55:05Z","timestamp":1217624105000},"page":"895-904","source":"Crossref","is-referenced-by-count":143,"title":["Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies"],"prefix":"10.1093","volume":"62","author":[{"given":"Theodoros","family":"Kelesidis","sequence":"first","affiliation":[{"name":"\u00a0Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece"},{"name":"\u00a0Department of Medicine, Caritas St Elizabeth's Medical Center, Tufts University School of Medicine, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drosos E.","family":"Karageorgopoulos","sequence":"additional","affiliation":[{"name":"\u00a0Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iosif","family":"Kelesidis","sequence":"additional","affiliation":[{"name":"\u00a0Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece"},{"name":"\u00a0Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew E.","family":"Falagas","sequence":"additional","affiliation":[{"name":"\u00a0Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece"},{"name":"\u00a0Department of Medicine, Henry Dunant Hospital, Athens, Greece"},{"name":"\u00a0Department of Medicine, Tufts University School of Medicine, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2008,8,1]]},"reference":[{"key":"2021081609504447100_DKN311C1","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ijantimicag.2006.12.012","article-title":"Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era?","volume":"29","author":"Falagas","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"2021081609504447100_DKN311C2","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/jac\/dkm356","article-title":"Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case\u2013control study","volume":"60","author":"Falagas","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2021081609504447100_DKN311C3","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.tim.2006.07.008","article-title":"The \u03b2-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter","volume":"14","author":"Livermore","year":"2006","journal-title":"Trends Microbiol"},{"key":"2021081609504447100_DKN311C4","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1128\/AAC.49.8.3136-3146.2005","article-title":"Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis","volume":"49","author":"Kasiakou","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2021081609504447100_DKN311C5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10096-007-0456-4","article-title":"Antimicrobial susceptibility of multidrug-resistant Gram-negative bacteria to fosfomycin","volume":"27","author":"Falagas","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2021081609504447100_DKN311C6","first-page":"176","article-title":"Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options","volume":"9","author":"Vergidis","year":"2008","journal-title":"Curr Opin Investig Drugs"},{"key":"2021081609504447100_DKN311C7","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/jac\/dki248","article-title":"Tigecycline","volume":"56","author":"Pankey","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2021081609504447100_DKN311C8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.diagmicrobio.2005.06.001","article-title":"In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004)","volume":"52","author":"Hoban","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021081609504447100_DKN311C9","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/jac\/dki291","article-title":"Tigecycline: what is it, and where should it be used?","volume":"56","author":"Livermore","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2021081609504447100_DKN311C10","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1471-4892(01)00081-9","article-title":"Glycylcyclines: third-generation tetracycline antibiotics","volume":"1","author":"Chopra","year":"2001","journal-title":"Curr Opin Pharmacol"},{"key":"2021081609504447100_DKN311C11","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/AAC.49.2.791-793.2005","article-title":"AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii","volume":"49","author":"Ruzin","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2021081609504447100_DKN311C12","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1128\/AAC.47.3.972-978.2003","article-title":"Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1","volume":"47","author":"Dean","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2021081609504447100_DKN311C13","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1128\/AAC.47.2.665-669.2003","article-title":"AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis","volume":"47","author":"Visalli","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2021081609504447100_DKN311C14","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1469-0691.2006.01621.x","article-title":"Tigecycline: in vitro performance as a predictor of clinical efficacy","volume":"13","author":"Hawkey","year":"2007","journal-title":"Clin Microbiol Infect"},{"key":"2021081609504447100_DKN311C15","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1099\/jmm.0.46747-0","article-title":"The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa","volume":"55","author":"Falagas","year":"2006","journal-title":"J Med Microbiol"},{"key":"2021081609504447100_DKN311C16","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1128\/AAC.43.4.738","article-title":"In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936)","volume":"43","author":"Petersen","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2021081609504447100_DKN311C17","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/jac\/dkl514","article-title":"In vitro activity of tigecycline against carbapenem-susceptible and -resistant isolates of Klebsiella spp. and Enterobacter spp","volume":"59","author":"Woodford","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2021081609504447100_DKN311C18","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1128\/AAC.00322-06","article-title":"In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, Gram-negative and Gram-positive clinical isolates from Greek hospitals","volume":"50","author":"Souli","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2021081609504447100_DKN311C19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0732-8893(01)00269-3","article-title":"In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant Gram-positive blood stream infection isolates and strains producing extended-spectrum \u03b2-lactamases","volume":"40","author":"Biedenbach","year":"2001","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021081609504447100_DKN311C20","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1080\/00313020701684284","article-title":"In vitro activities of \u2018new\u2019 and \u2018conventional\u2019 antibiotics against multi-drug resistant Gram-negative bacteria from patients in the intensive care unit","volume":"39","author":"Ratnam","year":"2007","journal-title":"Pathology"},{"key":"2021081609504447100_DKN311C21","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1093\/jac\/dkm391","article-title":"In vitro activity of tigecycline against metallo-\u03b2-lactamase-producing Enterobacteriaceae","volume":"60","author":"Pliatsika","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2021081609504447100_DKN311C22","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1128\/AAC.01114-07","article-title":"Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-\u03b2-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program","volume":"52","author":"Castanheira","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2021081609504447100_DKN311C23","doi-asserted-by":"crossref","first-page":"807","DOI":"10.47102\/annals-acadmedsg.V36N10p807","article-title":"Susceptibility of multi-resistant Gram-negative bacilli in Singapore to tigecycline as tested by agar dilution","volume":"36","author":"Tan","year":"2007","journal-title":"Ann Acad Med Singapore"},{"key":"2021081609504447100_DKN311C24","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1128\/AAC.00155-06","article-title":"Antibiotic coresistance in extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline","volume":"50","author":"Morosini","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2021081609504447100_DKN311C25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/jac\/dki175","article-title":"Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents","volume":"56","author":"Bratu","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2021081609504447100_DKN311C26","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1128\/AAC.49.9.3910-3918.2005","article-title":"Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates","volume":"49","author":"Petersen","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2021081609504447100_DKN311C27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.diagmicrobio.2004.11.006","article-title":"In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001\u201302","volume":"51","author":"Bouchillon","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021081609504447100_DKN311C28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.diagmicrobio.2005.06.004","article-title":"In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004)","volume":"52","author":"Bouchillon","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021081609504447100_DKN311C29","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.diagmicrobio.2005.06.010","article-title":"Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates","volume":"52","author":"Fritsche","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021081609504447100_DKN311C30","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.diagmicrobio.2005.05.003","article-title":"Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections 2000\u201304","volume":"52","author":"Fritsche","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021081609504447100_DKN311C31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.diagmicrobio.2006.02.001","article-title":"Antimicrobial activity of tigecycline against recent isolates of respiratory pathogens from Asian countries","volume":"55","author":"Ko","year":"2006","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021081609504447100_DKN311C32","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ijantimicag.2006.07.010","article-title":"Activity of tigecycline against clinical isolates of Staphylococcus aureus and extended-spectrum \u03b2-lactamase-producing Escherichia coli in Granada, Spain","volume":"28","author":"Sorlozano","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"2021081609504447100_DKN311C33","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1128\/AAC.00210-06","article-title":"Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial","volume":"50","author":"Waites","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2021081609504447100_DKN311C34","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/jac\/dkl414","article-title":"Activity of tigecycline against ESBL-producing and AmpC-hyperproducing Enterobacteriaceae from south-east England","volume":"58","author":"Hope","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2021081609504447100_DKN311C35","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/jac\/dkm310","article-title":"Antimicrobial susceptibility among organisms from the Asia\/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline","volume":"60","author":"Reinert","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2021081609504447100_DKN311C36","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ijantimicag.2007.07.024","article-title":"Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel","volume":"30","author":"Samra","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"2021081609504447100_DKN311C37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jinf.2006.11.018","article-title":"Antimicrobial susceptibility among Acinetobacter calcoaceticus\u2013baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial","volume":"55","author":"Halstead","year":"2007","journal-title":"J Infect"},{"key":"2021081609504447100_DKN311C38","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.diagmicrobio.2006.10.013","article-title":"Antimicrobial susceptibility of extended-spectrum \u03b2-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial","volume":"57","author":"Hoban","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021081609504447100_DKN311C39","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1128\/JCM.02351-06","article-title":"Comparative in vitro antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality control","volume":"45","author":"Brown","year":"2007","journal-title":"J Clin Microbiol"},{"key":"2021081609504447100_DKN311C40","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.patbio.2007.07.003","article-title":"In vitro activity of tigecycline against strains isolated from diabetic foot ulcers","volume":"55","author":"Sotto","year":"2007","journal-title":"Pathol Biol (Paris)"},{"key":"2021081609504447100_DKN311C41","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ijantimicag.2006.10.019","article-title":"Regional variations in multidrug resistance among Enterobacteriaceae in the USA and comparative activity of tigecycline, a new glycylcycline antimicrobial","volume":"29","author":"DiPersio","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"2021081609504447100_DKN311C42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0732-8893(99)00092-9","article-title":"Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates","volume":"36","author":"Gales","year":"2000","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021081609504447100_DKN311C43","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1128\/AAC.47.1.400-404.2003","article-title":"Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates","volume":"47","author":"Milatovic","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2021081609504447100_DKN311C44","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/jac\/dkh232","article-title":"Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001\u20132002: the BSAC Bacteraemia Resistance Surveillance Programme","volume":"53","author":"Reynolds","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"2021081609504447100_DKN311C45","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.diagmicrobio.2004.08.007","article-title":"In vitro activities of tigecycline against clinical isolates from Shanghai, China","volume":"50","author":"Zhang","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021081609504447100_DKN311C46","doi-asserted-by":"crossref","first-page":"S315","DOI":"10.1086\/431673","article-title":"In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections","volume":"41","author":"Bradford","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2021081609504447100_DKN311C47","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.diagmicrobio.2005.05.002","article-title":"Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit","volume":"52","author":"Sader","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021081609504447100_DKN311C48","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.diagmicrobio.2005.05.004","article-title":"Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia","volume":"52","author":"Fritsche","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021081609504447100_DKN311C49","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.diagmicrobio.2006.07.005","article-title":"Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study","volume":"56","author":"Betriu","year":"2006","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021081609504447100_DKN311C50","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/jac\/dki489","article-title":"Epidemiological MIC cut-off values for tigecycline calculated from Etest MIC values using normalized resistance interpretation","volume":"57","author":"Kronvall","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2021081609504447100_DKN311C51","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1128\/AAC.00625-07","article-title":"Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline","volume":"51","author":"Tuckman","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2021081609504447100_DKN311C52","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/jac\/dkm202","article-title":"Acinetobacter spp. susceptibility to tigecycline: a worldwide perspective","volume":"60","author":"Curcio","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2021081609504447100_DKN311C53","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ijantimicag.2007.07.020","article-title":"Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections","volume":"30","author":"Sader","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"2021081609504447100_DKN311C54","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/jac\/dkm297","article-title":"Determination of disc breakpoints and evaluation of Etests for tigecycline susceptibility testing by the BSAC method","volume":"60","author":"Hope","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2021081609504447100_DKN311C55","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.diagmicrobio.2005.05.005","article-title":"Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents","volume":"52","author":"Sader","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021081609504447100_DKN311C56","first-page":"1147","article-title":"European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee. EUCAST technical note on tigecycline","volume":"12","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"2021081609504447100_DKN311C57","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1089\/sur.2005.058","article-title":"Predictors of efficacy and health resource utilization in treatment of complicated intra-abdominal infections: evidence for pooled clinical studies comparing tigecycline with imipenem-cilastatin","volume":"8","author":"Mallick","year":"2007","journal-title":"Surg Infect (Larchmt)"},{"key":"2021081609504447100_DKN311C58","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1128\/AAC.00813-07","article-title":"Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections","volume":"52","author":"Passarell","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2021081609504447100_DKN311C59","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.clinthera.2007.05.018","article-title":"Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin\/tazobactam, and tigecycline using Monte Carlo simulation","volume":"29","author":"Eagye","year":"2007","journal-title":"Clin Ther"},{"key":"2021081609504447100_DKN311C60","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1128\/AAC.01084-06","article-title":"Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections","volume":"51","author":"Meagher","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2021081609504447100_DKN311C61","article-title":"Integrated results of 2 phase 3 studies comparing tigecycline (TGC) with levofloxacin (LEV) in patients (pts) with community-acquired pneumonia (CAP) (abstract)","volume-title":"Presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 27\u201330 September 2006","author":"Tigecycline 308 Study Group; Tigecycline 313 Study Group","year":"2006"},{"key":"2021081609504447100_DKN311C62","doi-asserted-by":"crossref","first-page":"S354","DOI":"10.1086\/431676","article-title":"The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data","volume":"41","author":"Babinchak","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2021081609504447100_DKN311C63","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.diagmicrobio.2007.09.017","article-title":"Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 \u03b2-lactamase-producing Klebsiella pneumoniae epidemic clone","volume":"60","author":"Cobo","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021081609504447100_DKN311C64","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1179\/joc.2007.19.2.232","article-title":"Once-daily tigecycline therapy of multidrug-resistant and non-multidrug-resistant Gram-negative bacteremias","volume":"19","author":"Cunha","year":"2007","journal-title":"J Chemother"},{"key":"2021081609504447100_DKN311C65","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1592\/phco.27.7.1052","article-title":"Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae","volume":"27","author":"Daly","year":"2007","journal-title":"Pharmacotherapy"},{"key":"2021081609504447100_DKN311C66","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1086\/518706","article-title":"Diffuse cutaneous hyperpigmentation due to tigecycline or polymyxin B","volume":"45","author":"Knueppel","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2021081609504447100_DKN311C67","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-2334-5-88","article-title":"A multicenter trial of the efficacy and safety of tigecycline versus imipenem\/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]","volume":"5","author":"Oliva","year":"2005","journal-title":"BMC Infect Dis"},{"key":"2021081609504447100_DKN311C68","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1086\/526775","article-title":"Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline","volume":"46","author":"Anthony","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2021081609504447100_DKN311C69","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1086\/528719","article-title":"Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-\u03b2-lactamase in a Greek University Hospital","volume":"46","author":"Souli","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2021081609504447100_DKN311C70","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1179\/joc.2007.19.6.753","article-title":"Single daily high-dose tigecycline therapy of a multidrug-resistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes nosocomial urinary tract infection","volume":"19","author":"Cunha","year":"2007","journal-title":"J Chemother"},{"key":"2021081609504447100_DKN311C71","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1128\/JCM.01340-07","article-title":"Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-\u03b2-lactamase- producing Escherichia coli","volume":"46","author":"Krueger","year":"2008","journal-title":"J Clin Microbiol"},{"key":"2021081609504447100_DKN311C72","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1469-0691.2007.01860.x","article-title":"Extended-spectrum \u03b2-lactamases and the permeability barrier","volume":"14","author":"Martinez-Martinez","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"2021081609504447100_DKN311C73","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1128\/JCM.00089-07","article-title":"Validation and reproducibility assessment of tigecycline MIC determinations by Etest","volume":"45","author":"Bolmstrom","year":"2007","journal-title":"J Clin Microbiol"},{"key":"2021081609504447100_DKN311C74","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/jac\/dki386","article-title":"Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines H2005","volume":"56","author":"Hope","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2021081609504447100_DKN311C75","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1128\/AAC.44.4.943-949.2000","article-title":"In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various Gram-positive and Gram-negative bacteria","volume":"44","author":"van Ogtrop","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2021081609504447100_DKN311C76","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1592\/phco.27.8.1198","article-title":"Rapid development of Acinetobacter baumannii resistance to tigecycline","volume":"27","author":"Reid","year":"2007","journal-title":"Pharmacotherapy"},{"key":"2021081609504447100_DKN311C77","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1592\/phco.27.7.980","article-title":"Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii","volume":"27","author":"Schafer","year":"2007","journal-title":"Pharmacotherapy"},{"key":"2021081609504447100_DKN311C78","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jac\/dkn165","article-title":"Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence","volume":"62","author":"Karageorgopoulos","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2021081609504447100_DKN311C79","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/jac\/dkm397","article-title":"MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli","volume":"61","author":"Keeney","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2021081609504447100_DKN311C80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/mdr.2006.9990","article-title":"RamA a transcriptional regulator AcrAB an RND-type efflux pump are associated with decreased susceptibility to tigecycline in Enterobacter cloacae","volume":"13","author":"Keeney","year":"2007","journal-title":"Microb Drug Resist"},{"key":"2021081609504447100_DKN311C81","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ijantimicag.2005.02.013","article-title":"Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline","volume":"25","author":"Conte","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"2021081609504447100_DKN311C82","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1128\/AAC.01099-06","article-title":"In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii","volume":"51","author":"Scheetz","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2021081609504447100_DKN311C83","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/jac\/dkm459","article-title":"In vitro activities of tigecycline combined with other antimicrobials against multiresistant Gram-positive and Gram-negative pathogens","volume":"61","author":"Vouillamoz","year":"2008","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/62\/5\/895\/39742878\/jac_62_5_895.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/62\/5\/895\/39742878\/jac_62_5_895.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T08:11:02Z","timestamp":1684483862000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/62\/5\/895\/725855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,1]]},"references-count":83,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2008,8,1]]},"published-print":{"date-parts":[[2008,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkn311","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2008,11]]},"published":{"date-parts":[[2008,8,1]]}}}